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Skeletal Muscle Atrophy (SMA) is a phenomenon
found in many diseases and disorders.  SMA is
characterized by protein degradation induced by
various pathways.   Ten years ago, little was known
about the mechanisms that lead from these
disorders to protein degradation.  Current research
focuses on the mechanisms thought to induce
SMA.  It is now known that many of these pathways
involve ubiquitin conjugate accumulation and
increased proteasome activity resulting in rapid
protein degradation and decreased synthesis.  HIV
associated proteins, such as Vpr, cause
overexpression of atrogin-1 which promotes
atrophy.  Cachexia operates mainly through the
IKK/NF_B pathway and MuRF-1 Ub-ligase
overexpression causes SMA. In contrast, the onset
of oxidative stress increases intracellular calcium
levels, activating endoproteases and stimulating
myofilament degradation.  Lastly, diabetes acts in a
similar way.  Low insulin levels trigger ub-
conjugation and proteasome activity leading to
SMA.  In order to treat SMA in the aforementioned
disorders, specified inhibitor drugs are being
considered for hindering the pathway.  This review
proposes to use the HIV virus as a model to
investigate how these diseases induce SMA with
further investigations of the mechanisms from HIV
to the aforementioned diseases.  Possible
treatments are associated with the reverse
pathway, hypertrophy, which suppresses protein
degradation and increases synthesis.
Introduction
Skeletal Muscle Atrophy (SMA) is a phenomenon
common in many diseases and disorders such as
starvation, disuse, denervation, sepsis, acidosis,
cancer, diabetes, HIV/AIDS, oxidative stress, and more
(Goldberg et al., 2004).
Ten years ago, it was assumed that these
illnesses were related because they have many
symptoms in common (Goldberg et al., 1986).  Until
recently, there had only been correlations between the
appearance of SMA with these disorders and diseases
but no direct evidence of their correlation existed.
SMA is characterized as the rapid degradation of
proteins in voluntary muscles.  With SMA, the capacity
of the muscles to function is diminished.  The
mechanisms for this were previously unknown.  For
example, it was thought that atrophy during fasting was
somehow caused primarily by enzymes and
intracellular calcium uptake, though it was neither
definitive nor specific (Russell et al., 1984).
Because SMA is associated with many different
*This paper was written for BIO221 Cell and Molecular Biology taught by
Dr. Shubhik K. DebBurman.
disorders, it is possible that there are many different
pathways leading to protein degradation.  How many
are there?  What is the nature of these pathways?
Which diseases, if any, follow the same pathway?
What specifically happens in these pathways?  Though
it has been shown that these pathways have an effect
on SMA, there is still much that is not understood.
This study focuses on four different disorders that
follow different pathways to SMA: HIV/AIDS, cachexia,
oxidative stress, and diabetes.  Each of these illnesses
is highly studied and much information has been
discovered in the last decade.
HIV/AIDS
HIV/AIDS has an exponential rate of infection
concentrated largely in African women and children.
There are no cures for HIV/AIDS and many aspects of
the disease are still a mystery.
In the early 1990’s, studies showed that one of
the earliest clinical symptoms of HIV was weight loss
and muscle wasting.  When comparing muscle mass of
a healthy person to that of an HIV/AIDS patient, the
muscle mass of the HIV/AIDS patient was significantly
lower.  This was the first evidence that SMA is
associated with HIV/AIDS (Gheradi et al., 1992).
Cachexia
Cachexia is a symptom of cancer known as a
wasting syndrome characterized by the loss of adipose
and muscle tissues.  Approximately half of all cancer
patients are afflicted with cachexia.  In carcinomas of
the pancreas and stomach, patients have an 80%
chance of developing cachexia.  Women with breast
cancer have a 40% chance of developing this disorder
(Iida et al., 1994).
Cachetic cancer patients experience at least a
10% decrease in body weight and usually die within six
months of developing the disorder (Iida et al., 1994).
Cachexia is one of the most significant causes of
mortality in cancer.
Oxidatvie Stress
Oxidative stress is the general term for the level of
oxidative damage in a cell.  The oxidative damage is
caused by reactive oxygen species, such as free
radicals and peroxides that can affect a specific
molecule or the entire organism.  These species are
usually by-products of other metabolic functions within
a cell.
A cell is very sensitive to its redox status because
the presence of oxidative stress increases intracellular
calcium levels.  Goldberg, et al. (1986) demonstrated
that SMA was correlated with these higher calcium
levels.
Diabetes Mellitus
 Diabetes mellitus is a disease connected to
insulin levels in the body.  When insulin is not
manufactured properly or at all, diabetes develops.
Type 1 diabetes is induced in children who
consume excessive fats and sugars with little to no
exercise.   Type 2 diabetes manifests in middle-aged
people due to insulin resistance.  This type of diabetes
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is thought to be influence more by genetics than Type
1.
Studies have shown that insulin action was
normal in nondiabetics.  In diabetics, however, the level
of insulin action in muscle cells was decreased.  This
was correlated with both a loss of muscle tissue and a
build up of adipose tissue (Kelley et al., 1993).
All four of these disorders have been connected
to SMA.  We will show how these disorders lead to
protein degradation and how, if at all, they are linked to
each other. (Figure 1)
HIV and SMA
The most direct pathway from HIV to SMA is through
the HIV Type-1 accessory protein, Vpr.  Vpr is one of
six accessory proteins produced in the body after the
HIV genomic information is integrated into the host
genome of a cell.  It has several functions as a
modulator of the host cell’s activity.  The most specific
of these functions is that of nuclear translocation of the
HIV-1 pre-integration complex. However, as part of its
role in modulating the host cell, Vpr arrests the cell at
the G2/M phase.  This occurs when Vpr is present and
binds to 14-3-3 proteins to change binding specificity to
that of Cdc25C to produce a Cdc25C and 14-3-3
protein complex (Kino et al., 2005).  Thus, Cdc25C is
prevented from entering the nucleus and the cell cycle
is arrested. This relationship between Vpr and 14-3-3
proteins is responsible for the first of two major roles of
Vpr in leading to SMA, blocking the effects of insulin on
forkhead transcription factors (FOXO).
Vpr Blocks Insulin Effects on FOXO
In a normal cell, insulin activates the PI3K/AKT
pathway via phosphorylation.  This leads to the
phosphorylation of the serine and threonine residues of
FOXO, which create binding sites for 14-3-3 proteins
(Kino et al., 2005).  When these 14-3-3 proteins bind to
the appropriate sites, FOXO is prevented from passing
into the nucleus and transcribing the ubiquitin ligase,
Atrogin-1, which is responsible for protein degradation
and ultimately SMA (Goldberg et al., 2004).
Therefore, in order to antagonize the effects of
insulin on FOXO, Vpr must prevent 14-3-3 proteins
from binding to serine and threonine residues of FOXO.
By binding to the 14-3-3 proteins, Vpr is competitively
inhibiting the crucial role that 14-3-3 proteins have on
FOXO. This not only allows FOXO into the nucleus to
transcribe Atrogin-1 but also terminates the
translocation activity of 14-3-3 proteins which would
allow FOXO already in the nucleus to be exported back
into the cytoplasm (Kino et al., 2005).
Vpr and Glucocorticoid Hypersensitivity
Vpr directly binds to the glucocorticoid receptor
(GR) on a cell membrane, which potentiates the action
of the GR on its responsive promoters.  In doing so, Vpr
acts as a nuclear receptor co-activator along with the
host cell’s co-activator p300/CBP. This binding and co-
activation of Vpr to the GR leaves the latter highly
sensitive to the presence of glucocorticoids (Kino et al.,
2004).
If the GR is highly sensitive, the cell acts as
though a large quantity of glucocorticoids is present.  In
this case, levels of insulin or the insulin growth factor
(IGF-1) decrease.  The lack of IGF-1 leads to the
dephosphorylation and deactivation of the PI3K/AKT
pathways.  Subsequently, FOXO is not phosphorylated
and therefore allowed into the nucleus where it
transcribes the ub-ligase Atrogin-1 (Goldberg et al.,
2004). Therefore, by creating a level of hypersensitivity
for the GR, Vpr triggers a mechanism leading to SMA.
Indirect Pathways from HIV to SMA
The high levels of cytokines, specifically tumor
necrosis factor-_ (TNF- _), which is known to activate
the nuclear factor NF_B, are characteristic of HIV.
Activation of this pathway stimulates cachexia in the
same way as cancer-associated cachexia which leads
to protein degradation.
Another role of TNF-_ is that of development and
maintenance of inflammation during infection. In the
gastrointestinal tract (GI tract), TNF-_ causes local
mucosal inflammation which leads to extreme oxidative
stress within the body.  Oxidative stress induces SMA
through many different mechanisms.
Lastly, HIV is correlated with insulin resistance.
Insulin resistance is one of the characteristics of
diabetes.  Therefore HIV can lead to diabetes which
leads to SMA.
Cancer Cachexia and SMA
Muscle degradation occurs in cancer cachexia through
the IKK/NF_B pathway and the ubiquitin ligase MURF1.
This pathway promotes tumor formation.  Therefore, the
muscle loss in cancer cachexia is not because of the
associated anorexia but is in response to the tumor
(Diffee et al., 2002).
The transcription factor NF_B is held in the
cytoplasm when it is bound to I_B_. In response to an
outside stress, such as a proinflammatory cytokine, I_B
phosphorylates the serine residues S32 and S36 on
I_B_, which causes it to degrade (Cai et al., 2004).
NF_B is no longer held in the cytoplasm and it
translocates to the nucleus.  As a transcription factor, it
regulates MURF1 protein production and MyoD mRNA.
MURF1 levels increase and MyoD levels decrease.
NF_B also induces transcription of its own inhibitor,
I_B_ (Ladner et al., 2003).
In a study done by Cai et al. (2004), mice were
engineered to have constitutively active I_B (MIKK
mice) or to have the I_B_ phosphorylation sites blocked
(MISR mice).  To simulate conditions of cancer
cachexia, they induced tumor growth outside of the
muscle.  The NF_B activity increased by 6-fold in wild
Figure 1. Correlation from HIV to diabetes, cachexia,
oxidative stress.
Mechanisms to SMA are unknown
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type mice whereas MISR mice had no significant
change.  The NF_B was unable to translocate to the
nucleus, because it was still bound to the I_B_.  In
MIKK mice, muscle mass and cross-sectional area of
muscle fibers were significantly lowered when
compared to wild type mice.  In these mice, the
percentage of amino acids and their metabolites was
increased by 45% which indicates increased protein
catabolism.  The constitutively active NF_B pathway in
these mice caused SMA.
During their study, atrogin-1 was neither
stimulated nor inhibited, suggesting that NF_B is a
distinct yet parallel pathway.
How do cytokine levels affect SMA?
Tumor Necrosis Factor-_ (TNF-_) is a
proinflammatory cytokine and activates the NF_B
pathway in a biphasic manner  (Ladner et al., 2003).
The first transient phase is short, about one hour, while
the second phase lasts for 24-36 hours.  The second
phase is only activated if the TNF levels are high
throughout the entire period of time.  This occurs during
cancer cachexia which explains the constant activation
of the NF_B pathway.  It was mentioned before that
NF_B transcribes its own inhibitor, I_B_.  After its
transcription, I_B_ is transported to the nucleus and
binds to NF_B, which causes the complex to move
back into the cytoplasm.  The second phase is the more
potent of the two and the major cause of muscle
degradation.
It is unknown how TNF activates NF_B, although
it may go through the aforementioned IKK pathway.  It
is known that TNF causes the increase in the level of
MURF1 and decreases the level of MyoD mRNA,
causing skeletal muscle atrophy.  Ladner et al. (2003)
study found that TNF alone was unable to cause full
skeletal muscle atrophy.  However, when it was
coupled with the cytokine INF_, the results were much
more drastic.  This suggests that multiple cytokines are
necessary for degradation.
What is the substrate of MURF1?
The actual substrate of MURF1 in skeletal
muscle is unknown.  In a study conducted by Kedar et
al. (2004), MURF1 was found to bind to troponin I in
cardiac muscle.  MURF1 decreases the level of
troponin I by inducing its ubiquitination and
proteasome-dependent degradation.  Troponin I is
present in skeletal muscle, but it is unknown whether or
not MURF1 binds to troponin I outside of the cardiac
muscle.
Why is no new muscle forming?
The NF_B pathway also prevents skeletal muscle
differentiation and therefore synthesis of new muscle
(Diffee et al., 2002).  NF_B prevents skeletal muscle
differentiation by inhibiting the production of MyoD
mRNA.  MyoD helps control the fusion of myoblasts into
multinucleated myotubes.  Without MyoD, an injured
muscle cannot repair itself after damage, but a lack of
MyoD has not been shown to inhibit development.
When TNF is present in undifferentiated
myocyctes the level of MyoD mRNA is drastically
reduced (Diffee et al., 2002).  Other differentiation
proteins were unaffected.  The same results occured for
differentiated myocytes and mouse muscle in vivo.
TNF and the NF_B pathway reduce the level of MyoD
mRNA and therefore leave the muscle unable to repair
itself.
NF_B not only causes muscle degradation but
prevents synthesis of new muscle, making cancer
cachexia a deadly disease.  In fact, one-third of cancer
related deaths occur because of cachexia, not tumor
burden (Guttridge et al., 2000).  Direct inhibition of the
NF_B pathway may help reduce the muscle loss
associated with cancer cachexia.
Oxidative Stress and SMA
Oxidative stress regulates atrophy pathways during
periods of prolonged disuse. We will use disuse as
model to understand what occurs when  symptoms of
HIV/AIDS introduce oxidative stress.
Experimental Models
Two models are used to study the mechanism of
atrophy in humans.  Rat hindlimb suspension models
demonstrate immediate decrease in protein synthesis
on the onset of unloading, which becomes steady at
approximately 48 hours. Slow-twitch fibers (type I) are
observed to atrophy more readily than any other muscle
type in this form of unloading (Powers et al., 2005).
Another disuse model investigates diaphragm wasting
by a mechanical ventilator (MV). The MV completely
inactivates the diaphragm. This is clinically significant
because diaphragm atrophy contributes to difficulty in
weaning from the MV. Fast-twitch fibers (type II) are
degraded in the diaphragm by MV (Shanely et al.,
2002).
Proteolytic Pathways in SMA
There are three proteolytic pathways in the
skeletal muscle caused by ROS that can be activated a
variety of ways. Some of these pathways work together
and some work separately. These pathways involve
calcium activated lysosomal proteases (i.e. calpain),
endoproteases like caspase-3, and the 20S/26S
proteasome system (Powers et al., 2005).
These components are unique features in the
three proteolytic pathways. Proteases are known to
degrade proteins and, in some cases, lead to apoptosis
(Wang et al., 1998). Calpain is in the class of ubiquitous
proteases (Koh et al., 2000). Both caspases and
calpain belong to a group of cysteine proteases.
Cystein proteases are sensitive to the redox condition
of a cell. These enzyme proteases have the ability to
cleave other proteins. Caspases are pivotal factors in
cellular apoptosis (Wang et al., 1998). The 20S/26S
proteasome system degrades actomyosin complexes
after cleavage by calpain or caspase-3.
Mediation of Intracellular Calcium Levels
There are two known theoretical mechanisms
that work together to regulate intracellular calcium
levels. The first mechanism involves disuse within
skeletal muscles. Muscular inactivity has been shown to
increase oxidative stress (Shanely et al., 2002).
Reactive oxygen intermediates play a role in the
formation of reactive aldehydes (i.e. 4-hydroxy-2,3-
trans-non-enal) which decreases activity of plasma
membrane calcium ATPase activity (Powers et al.,
2005). The inactivity of this enzyme hinders the
movement of calcium in and out of the cell. The second
mechanism elicits the indefinite presence of calcium
within the cell. The sarcoplasmic reticulum is the
primary source of calcium for skeletal muscles. In the
presence of ROS, antioxidant proteins such as heme
oxygenase-1 (HO-1) are upregulated. Calsequestrin,
which sequesters calcium to the cell interior, is also
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upregulated. Careticulun, however, which inactivates
calcium in high capacity and low affinity, is not
upregulated. ROS actually reduces the function of
careticulun as well (Hunter et al., 2001). In short, these
two mechanisms translate to a high concentration of
intracellular calcium. This investigation is significant
because the activity of the proteolytic pathways
mentioned above depend on a high concentration of
calcium.
Calpain-Mediated Release of Myofilaments
The first proteolytic pathway activates a
lysosomal or cysteine protease, calpain, by the
increase of intracellular calcium (Hunter et al., 2001).
Calpain then cleaves structural proteins that anchor
actomyosin complexes within the sarcomere of the
myofibril. These anchor proteins are known as talin and
vinculin. The cleavage of talin and vinculin release
actomyosin complexes. The third proteolytic pathway
mentioned, 20S/26S proteasome, is now apt to degrade
the actomyosin complex leading to the onset of skeletal
muscle atrophy. The 20S/26S proteasome cannot
degrade proteins in the sarcomere unless they are
ubiquinated (covalently marked) for degradation by
calpain (Powers et al., 2005).
Calpain Inhibitor
It is essential to note that calpain can be inhibited
by another molecule. Calpastatin is a regulatory protein
that binds to calpain in the presence of calcium to
inhibit its function (Koh et al., 2000). Overexpression of
calpastatin in a transgene mouse has been shown to
reduce muscle atrophy by 30% (Tidball et al., 2002).
Another note shows that calpastatin breakdown
precedes apoptosis (Wang et al., 1998). This is
significant because it shows that a high concentration of
calpastatin indicates myofibril viability and the lack of it
precedes cell death.
Caspase-3 and SMA
The second proteolytic pathway mentioned
involves the endoprotease caspase-3. Caspase-3 can
be activated in two ways. Both ways stem from the
presence of ROS. In the first way, caspase-3 can be
activated by increased calpain activity. Caspase-3 has
the same cleavage properties of calpain and has been
shown to cleave to the same sites of talin and vinculin
(Wang et al., 1998). The second way that caspase-3
can be activated is by the release of cytochrome c from
the mitochondria. Cytochrome c is an essential heme
protein in the electron transport chain (Powers et al.,
2005). Superoxide anions (ROS) are a by-product of
mitochondrial electron transport (Reid et al., 2001).
Diabetes and SMA
As previously stated, scientists have noticed a
correlation between symptoms in diabetes and SMA.
The main principle that scientists are currently trying to
resolve is what the correlation between symptoms of
diabetes, such as low available insulin levels, and the
increased activation of protein degradation.
What activates the Ubiquitin-proteasome pathway?
In muscle cells of rats, it has been documented
that insulin deprivation increases protein degradation
and that higher insulin levels suppress this degradation
(Mitch et al., 1999). Studies suggest that insulin levels
or insulin resistance activates some mechanism for
protein degradation (Mitch et al., 1999).
Mitch et al. (1999) hypothesized that insulin
levels are a signal for activation of an ubiquitin-
proteasome pathway. This was tested against acidosis
and gluccocorticoid signaling in rats with induced
diabetes.  First, normal rats were given oral NaCl or
NaHCO3 to develop acute acidosis.  The rate of protein
degradation was much higher than in the control and
that when inhibitors of lysosomal or Ca2+ dependent
proteolysis the rate did not differ.  This suggests that
the ubiquitin pathway is activated for protein
degradation (Mitch et al., 1999).
To ensure that the ubiquitin-proteosome pathway
was indeed activated, diabetic rats were fed NaCl or
NaHCO3 and the rate of protein degradation was
compared to non-diabetic rats with acidosis.  The
indicated showed that rates of protein degradation
between the two groups did not differ significantly.
The same experiment was repeated using
gluccocorticoids and similar results were found. Then
the diabetic rats were tested after treatment with insulin
for three days.  The rate of protein degradation was
lower in insulin treated rats than in non-insulin treated
diabetic rats (Mitch et al., 1999).
These results indicate that the lower insulin level
possibly signal the activation of the proteasome
pathway.  Levels of ubiquitin mRNA were also
measured in the previous study and found to be higher
(Mitch et al., 1999).  This further supports the idea that
low insulin levels activate a ubiquitin-proteasome
pathway.
Results of Pathway Activation
Goldberg et al. (1999) measured the amount of
Ub–conjugation in diabetic rats against that in non-
diabetic rats because ubiquitins tag proteins for
degradation.  The results showed that the amount of
Ub-conjugation by E3-_ Ub-ligase in diabetic rats was
greater than in non-diabetic rats.
It was also found that the amount of degradation
was sensitive to proteasome inhibitors.  For that
reason, it was concluded that both the amount of
conjugation and the rate at which conjugation occurred
increased.  It also suggested that there must be a third
factor that leads to SMA in diabetes.
Role of Proteasomes
With low insulin levels, the amount of
gluccocorticoids in the blood, i.e. gluclose, increases.
This increase in the gluccocorticoids and the activation
of ubiquitination then catalyzes
the formation of the 26S proteasome complex
(Attaix et al., 2004). The 26S proteasome is known to
degrade proteins that have been Ub-conjugated.  It has
been observed that during protein degradation in cell
cultures, there are high levels of the 26S proteasome
(Attaix et al., 2004).  The question, then, is what is
missing in between.
To test this, rats were treated with DX, a synthetic
gluccocorticoid, and their muscles were extracted for
examination.  Because the 26S proteasome is made
from the 19S and 20S components, and the 26S
proteasome is known to be highly expressed during
atrophy, the levels mRNA for the two components were
examined with high levels of gluccocorticoids.  Results
showed that the mRNA levels for the two components
rose as well as the enzymes that are known to work in
conjunction with the proteasome.
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This indicates that diabetes is linked to SMA
through the activation of the ubiquitin-proteasome
pathway.  First, low levels of insulin cause an increase
in the amount of gluccocorticoids (Mitch et al., 1999).
From the gluccocorticoids, there is an increase in
ubiquitination of muscle proteins (Goldberg et al.,
1999).  Because of the increased activity in the ubiquitin
pathway, there is increased transcription for the
components of the 26S proteasome.  Increased
proteasome formation in conjunction with increased Ub-
conjugation leads to a rapid protein degradation or SMA
(Attaix et al., 2004).
Therapies
SMA is a symptom of a variety of diseases and
disorders. Treatments are dependent on the pathology
of the disease.
Therapies for SMA in HIV are diverse; they
include appetite stimulates, anabolic andrgoenous
steroids, resistance training, and some growth
hormones and cytokine suppressors.  These therapies
are designed to treat the wasting syndrome and do not
treat HIV.
In cachexia, sodium salicylate is being tested as
a pharmacological inhibitor for the NFkB pathway (Cai
et al., 2004).  This method, however, has not yet been
approved.
There are three main therapies for treating SMA
in oxidative stress.  Nitric oxide has been shown to
inhibit calpain cleavage of talin and vinculin. Vitamin E
can reduce immobilization-induced muscle atrophy by
approximately 20% (Powers et al., 2005). Finally, a
therapy mentioned before, expression of calpastatin
transgene can cause reduction of muscle atrophy by
30% (Tidball et al., 2002).
The main treatments for diabetes are well studied and
revolve around insulin regulation, and insulin regulation
would lead to regulation of SMA in patients.
Conclusion
HIV, cachexia, oxidative stress, and diabetes each
express direct mechanisms leading to SMA  (Figure 2).
Each of these diseases or disorders involves the
activity of ubiqutin ligases and proteosome complexes.
These activities are supported by many studies to be
the characteristic mechanism to protein degradation.
The direct mechanisms leading to SMA from HIV,
cachexia, oxidative stress, and diabetes have been well
studied within the past few years.  However, the
connections between HIV to cachexia, oxidative stress,
and diabetes should be studied more in depth.  With
diseases such as sarcokaposi, an AIDS-specific
cancer, a direct pathway from HIV to cancer may be
evident. The relationship between diabetes and
oxidative stress need to be studied to find specific links
leading from HIV. If direct pathways can be identified,
HIV could be used as a model to investigate many
more mechanisms leading to disease and ultimately to
SMA.
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